PharmaCyte Biotech, Inc.

- 15 AUG 2022
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board
LAS VEGAS, NV, August 15, 2022 — (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of
Read more →
- Posted in
- News
- 28 JUL 2022
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
– 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders – Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances to Iroquois with History of Value Destruction – Proposes 15-Person Board Which is Operationally Inefficient, Violates the Bylaws, and Would Unnecessarily Waste Company Resources – Attempts to Amend Bylaws to
Read more →
- Posted in
- News
- 21 JUL 2022
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte has complied
Read more →
- Posted in
- News
- 19 JUL 2022
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further
Read more →
- Posted in
- News
- 11 JUL 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022. Cash Position PharmaCyte had $85.4 million in cash and cash equivalents as
Read more →
- Posted in
- News
- 05 JUL 2022
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of a study to determine whether a previous established quantitative real-time PCR (qRT-PCR) could be used as a quality control test for its CypCaps™
Read more →
- Posted in
- News
- 15 JUN 2022
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022: We Take Issue with Iroquois’
Read more →
- Posted in
- News
- 13 JUN 2022
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO) being held at the San
Read more →
- Posted in
- News
- 08 JUN 2022
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following letter to its shareholders in response to the concerns expressed by Iroquois Capital Management (Iroquois) in its letter to the PharmaCyte
Read more →
- Posted in
- News
- 02 JUN 2022
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Board of Directors (Board) has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.
Read more →
- Posted in
- News

Press Releases